Birchview Capital’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Birchview Capital’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.26M	Buy	+40,601	New	+$1.08M	0.73%	34

Other funds holding IRLA

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Gen-Wealth Partners Zeeland, Michigan $356M AUM 21.02% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Birchview Capital's IRLA Position: Q3 2026 in Review

Birchview Capital opened a new position in IRulya Therapeutics Inc. Common Stock (IRLA) in Q3 2026: 40,601 shares worth $1.26M. The stake represents 0.73% of the portfolio and ranks #34 among its holdings.

21 funds tracked by Wall St. Rank hold IRLA as of Q3 2026.

Birchview Capital held 40,601 shares of IRulya Therapeutics Inc. Common Stock worth $1.26M as of Q3 2026.
IRulya Therapeutics Inc. Common Stock was a new Birchview Capital position in Q3 2026.
IRulya Therapeutics Inc. Common Stock made up 0.73% of Birchview Capital's portfolio in Q3 2026, its #34 holding.
21 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2026.

Based on Birchview Capital's 13F filing for Q3 2026, filed 13 Nov 2026.